- Report
- January 2026
- 192 Pages
Global
From €3185EUR$3,545USD£2,728GBP
€3539EUR$3,939USD£3,031GBP
- Report
- January 2026
- 181 Pages
Global
From €3185EUR$3,545USD£2,728GBP
€3539EUR$3,939USD£3,031GBP
- Report
- June 2026
- 194 Pages
Global
From €3185EUR$3,545USD£2,728GBP
€3539EUR$3,939USD£3,031GBP
- Report
- November 2025
- 182 Pages
Global
From €3185EUR$3,545USD£2,728GBP
€3539EUR$3,939USD£3,031GBP
- Report
- February 2026
- 250 Pages
Global
From €4034EUR$4,490USD£3,455GBP
- Report
- February 2026
- 250 Pages
Global
From €4034EUR$4,490USD£3,455GBP
- Report
- February 2026
- 250 Pages
Global
From €4034EUR$4,490USD£3,455GBP
- Report
- August 2026
- 285 Pages
Global
From €5255EUR$5,850USD£4,501GBP
- Report
- August 2026
- 326 Pages
Global
From €5255EUR$5,850USD£4,501GBP
- Report
- August 2026
- 184 Pages
Global
From €5255EUR$5,850USD£4,501GBP
- Report
- November 2025
- 200 Pages
Global
From €7142EUR$7,950USD£6,117GBP
- Report
- May 2026
- 350 Pages
Global
From €4446EUR$4,949USD£3,808GBP
- Drug Pipelines
- May 2026
- 150 Pages
Global
From €2505EUR$2,789USD£2,146GBP
- Report
- May 2026
- 150 Pages
Global
From €2425EUR$2,699USD£2,077GBP
- Report
- June 2026
- 132 Pages
Global
From €4267EUR$4,750USD£3,655GBP
- Report
- April 2026
- 180 Pages
Global
From €4267EUR$4,750USD£3,655GBP
- Report
- October 2025
- 160 Pages
Global
From €2839EUR$3,160USD£2,432GBP
€3548EUR$3,950USD£3,039GBP
- Report
- March 2026
- 199 Pages
Global
From €4487EUR$4,995USD£3,844GBP
- Report
- November 2025
- 150 Pages
Global
From €4357EUR$4,850USD£3,732GBP
- Report
- November 2025
- 200 Pages
Global
From €7142EUR$7,950USD£6,117GBP

Paclitaxel is a chemotherapy drug used to treat breast cancer. It is a semi-synthetic derivative of the natural product Taxol, which is extracted from the bark of the Pacific yew tree. Paclitaxel works by interfering with the normal process of cell division, preventing cancer cells from dividing and growing. It is typically used in combination with other drugs, such as doxorubicin, to treat advanced stages of breast cancer.
Paclitaxel is available in both intravenous and oral formulations, and is often used in combination with other drugs to treat metastatic breast cancer. It is also used to treat other types of cancer, such as ovarian and lung cancer.
Paclitaxel is marketed by several pharmaceutical companies, including Bristol-Myers Squibb, Pfizer, and Sanofi. It is also available as a generic drug in some countries.
Companies in the Paclitaxel market include Bristol-Myers Squibb, Pfizer, Sanofi, Mylan, Teva Pharmaceuticals, and Apotex. Show Less Read more